Abbott Laboratories (NYSE:ABT): After meeting with Abbott’s management, Wells Fargo is more convinced that the company is a compelling investment. The firm expects the company’s EPS to increase at a compound annual growth rate of 11.8 percent from 2013 to 2017, and it believes that the company’s diagnostics business is performing strongly. The firm keeps an Outperform rating on the stock.
SAP (NYSE:SAP): BMO Capital sees SAP’s purchase of Hybris as being positive, noting that the deal elevates SAP to among the top three players in ecommerce. Although the integration of hybris will be relatively easy for SAP, the firm keeps a Market Perform rating on the shares.
Endo Health (NASDAQ:ENDP): Leerink has brought its rating on Endo from Market Perform to Outperform, citing the company’s new 2013 outlook, which the firm views as achievable, and the company’s restructuring. Leerink also raised its price target for shares to $48 from $37
Vera Bradley (NASDAQ:VRA): Following weak Q1 results, Piper Jaffray has lowered its rating on the shares from Overweight to Neutral, citing decelerating sales and gross margins as well as the management changes. The firm also lowered its price target for shares to $24 from $32.